The estimated Net Worth of Jorma Routti is at least 64.6 千$ dollars as of 26 March 2019. Jorma Routti owns over 30,000 units of FibroGen Inc stock worth over 64,616$ and over the last 10 years Jorma sold FGEN stock worth over 0$.
Sign up
Jorma Routti FGEN stock SEC Form 4 insiders trading
Jorma has made over 11 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Jorma exercised 30,000 units of FGEN stock worth 682,500$ on 26 March 2019.
The largest trade Jorma's ever made was exercising 30,000 units of FibroGen Inc stock on 26 March 2019 worth over 682,500$. On average, Jorma trades about 7,176 units every 70 days since 2014. As of 26 March 2019 Jorma still owns at least 161,540 units of FibroGen Inc stock.
You can see the complete history of Jorma Routti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jorma Routti's mailing address?
Jorma's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Insiders trading at FibroGen Inc
Over the last 10 years, insiders at FibroGen Inc have traded over 188,593,537$ worth of FibroGen Inc stock and bought 106,523 units worth 1,309,423$ . The most active insiders traders include Rory B Riggs、Thomas B Neff、Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 6,963$. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth 25,884$.
What does FibroGen Inc do?
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
What does FibroGen Inc's logo look like?
Complete history of Jorma Routti stock trades at FibroGen Inc
FibroGen Inc executives and stock owners
FibroGen Inc executives and other stock owners filed with the SEC include:
-
Kin-Hung Yu,
Chief Medical Officer -
James Schoeneck,
Chairman of the Board -
Elias Kouchakji,
Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance -
Christine Chung,
Senior Vice President, China Operations -
Pat Cotroneo,
Chief Financial Officer -
Enrique A. Conterno,
CEO & Director -
Dr. Elias Kouchakji,
Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance -
Pat Cotroneo,
Exec. Advisor to CEO -
Suzanne Blaug,
Independent Director -
Thane Wettig,
Chief Commercial Officer -
Dr. Mark Eisner M.D., M.P.H.,
Chief Medical Officer -
Thomas Kearns,
Lead Independent Director -
Jeffrey Edwards,
Independent Director -
Rory Riggs,
Independent Director -
Gerald Lema,
Independent Director -
Jeffrey Henderson,
Independent Director -
Maykin Ho,
Independent Director -
Kalevi Kurkijarvi,
Independent Director -
Toshinari Tamura,
Independent Director -
James A. Schoeneck,
Chairman -
Benjamin Cravatt,
Director -
Aoife Brennan,
Director -
Thane Wettig,
Chief Commercial Officer -
Percy Carter,
Chief Scientific Officer -
Enrique Conterno,
Chief Executive Officer, Director -
Dr. John J. Hunter Ph.D.,
Chief Scientific Officer -
Dr. Michael J. Martinelli,
Sr. VP of Technical Devel. -
Juan Graham,
Chief Financial Officer -
Dr. Barry A. Berkowitz Ph.D.,
Founder -
Jorma Routti,
Director -
K Peony Yu,
Chief Medical Officer -
Thomas B Neff,
Chief Executive Officer -
Mark Eisner,
EVP, Chief Medical Officer -
Julian N Stern,
Director -
Frank H Md Valone,
Chief Medical Officer -
Miguel Madero,
Director -
Pharma Inc. Astellas,
-
Juan Graham,
CHIEF FINANCIAL OFFICER -
Deyaa Adib,
Chief Medical Officer